About us

Sciarray specializes in developing proprietary biological technologies which have led to the development of a pipeline of clinical diagnostic products in five immunological and molecular methods: ELISA, chemiluminescent immunoassay(CLIA), microarray chip, rapid biochemical test, gene methylation and medical devices.
As a leading provider of China's clinical diagnostical and research products in the past few years, Sciarray has begun to be a main, broad-based health care company devoted to discovering new clinical and laboratory methods, new technologies and new ways to managethe disease diagnosis.
Addressing key challenges in the early screening and accurate diagnosis of systemic lupus erythematosus (SLE), Sciarray has discoved a new gene methylation biomareker-IFI44L for SLE diagnosis, disease therapeutic and relapse monitoring . The product has received the Second Prize of the National Science and Technology Progress , the China's Top Ten Medical Advances and NMPA's special approval for innovative medical devices. This biomarker fills the gaps in epigenetic diagnostics for SLE, and expected to be accepted into the SLE diagnosis and treatment guidelines of the American College of Rheumatology (ACR), the European League Against Rheumatism (EULAR), and China's CSTAR.
Sciarray has been driven by a constant goal: to advance medical laboratory science to help clinical technicans to work more efficiently and conveniently, to make people free fromtough laboratory work. That's our commitment. The promise of our company is in the promise that our work holds for health and for easy life.